Cellbion (308430.KQ) — Stock Score Summary

Cellbion (308430.KQ) has a MoatMap StockRank of 13/100 based on Quality (29/100), Value (34/100), and Momentum (33/100) factor scores. The current signal is STRONG SELL.

CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under...

Key Financial Metrics

Price$11.65
Market Cap$150M
Price/Book9.96
Return on Equity-35.1%
Return on Invested Capital-22.6%
Debt/Equity40.48
Gross Margin-2.9%
Operating Margin-399.0%
Revenue Growth27.7%
Free Cash Flow$-3K

Cellbion operates in the Biotechnology industry, part of the Healthcare sector (South Korea).

Frequently Asked Questions

What is Cellbion’s (308430.KQ) StockRank?
MoatMap’s StockRank for Cellbion (308430.KQ) is 13/100, with a Strong Sell signal. It is a composite of Quality (29), Value (34), and Momentum (33) factor ranks across MoatMap’s 19,000+ stock universe.
Does Cellbion have an economic moat?
Cellbion (308430.KQ) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Cellbion a buy, hold, or sell?
MoatMap’s current signal for Cellbion (308430.KQ) is Strong Sell, based on a StockRank of 13/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Cellbion in?
Cellbion (308430.KQ) operates in the Healthcare sector, specifically the Biotechnology industry (South Korea).
Browse all ranked stocks308430.KQ deep dive reportAI ChampionsHow we score stocksSense-check another stock